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Abstract
Over the course of the past decade, genome-wide association
studies (GWAS) have revolutionised our understanding of complex
disease genetics. One of the diseases that has benefitted most
from this technology has been Crohn’s disease (CD), with the
identification of autophagy, the IL-17/IL-23 axis and innate
lymphoid cells as key players in CD pathogenesis. Our increasing
understanding of the genetic architecture of CD has also
highlighted how a failure to suppress aberrant immune responses
may contribute to disease development – a realisation that is now
being incorporated into the design of new treatments. However,
despite these successes, a significant proportion of disease
heritability remains unexplained. Similarly, most of the causal
variants at associated loci have not yet been identified, and even
fewer have been functionally characterised. Because of the
inarguable rise in the incidence of CD in regions of the world that
previously had low disease rates, GWAS studies will soon have to
shift from a largely Caucasian focus to include populations from
other ethnic backgrounds. Future studies should also move beyond
conventional studies of disease susceptibility into phenotypically
driven ‘within-cases’ analyses in order to explore the role of
genetics in other important aspects of disease biology. These
studies are likely to include assessments of prognosis and/or
response to treatments and may be critical if personalised
medicine is ever to become a reality.
Keywords: Crohn’s disease, GWAS, Pharmacogenetics, prognosis,
susceptibility.
INTRODUCTION
Crohn’s disease (CD) and ulcerative colitis (UC),
collectively termed Inflammatory Bowel Disease
(IBD), are some of the most extensively and
successfully studied diseases in complex disease
genetics. However, genetic studies in CD were
not always successful. Initial efforts to identify
the genetic determinants of CD were performed
using linkage mapping and were largely
disappointing, often producing weak or
inconsistent signals.1 One exception to this was
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the discovery of NOD2 as a major CD
susceptibility gene2–4 – a finding that represents
one of the few successes of linkage mapping
across all diseases. The development of genome-
wide association studies (GWAS), which facilitate
a hypothesis-free comparison of allele frequencies
at thousands of single nucleotide polymorphisms
(SNPs) between cases and controls (Figure 1),
transformed the study of CD genetics and led to
the discovery of many CD susceptibility SNPs.
Nonetheless, the overall number of hits identified
in early, single cohort GWAS studies was typically
modest (between 1 and 10) due to relatively
small sample sizes and the resulting limitations in
study power.5–8 Fortunately, the combination of
a high disease heritability and a strong
collaborative spirit between research groups from
around the world meant that subsequent meta-
analyses could include much larger numbers of
samples and were accordingly far more successful
in identifying the genetic determinants of IBD.9–
12 For example, in 2008, the first international
meta-analysis was performed by combining
GWAS data from the UK, US and Franco-Belgian
IBD Genetics consortia13 – studies that had
individually identified a total of 10 susceptibility
loci.5,6,8 The gain in power that was afforded by
combining these data sets led to the
identification of 32 associated loci13 and
highlighted the value of collaborating to create
larger data sets for analysis. This study was
unsurprisingly followed 2 years later by an even
larger meta-analysis – incorporating ~22 000 cases
and ~29 000 controls from 13 different countries
– in which 71 susceptibility loci were identified.9
Subsequent larger studies, which have taken
advantage of more affordable genotyping
approaches (such as the Illumina Immunochip),
have increased this number even further, with
241 IBD susceptibility loci being confirmed in the
most recent analysis.14 Such advances clearly
demonstrate the power of GWAS to provide
novel insights into disease pathogenesis,
particularly when applied to an ever-increasing
sample size.15 Interestingly, the majority of these
loci increase the risk of both CD and UC,14 and
many of them alter susceptibility to other
immune-mediated diseases as well – including
diseases that are known to be related to IBD,
such as primary sclerosing cholangitis, psoriasis
and ankylosing spondylitis, and others that were
previously thought to be unrelated, such as type
1 diabetes and multiple sclerosis.16 Despite this
undoubted success, however, it is important to
note that most GWAS hits are only proxies for
the true causal variant(s) at each locus (with
which they are inherited through linkage
disequilibrium). Indeed, it was the realisation
that entire haplotypes could be interrogated by
genotyping just one of their constituent SNPs
that helped make GWAS possible in the first
place, as it meant that genome-wide genetic
variation could be captured using a tractable
number of variants (that could be incorporated
into a single genotyping chip) (Figure 1). As such,
to identify the functional consequences of these
associated haplotypes – and the mechanism by
which they alter disease risk – it will be
important to identify the causal variant(s) that is
ultimately responsible for the association. In
some cases, this may be possible using statistical
fine mapping – such as has recently been
performed by the International Inflammatory
Bowel Disease Genetic Consortium (IIBDGC)17 –
but in others, some form of functional
characterisation of the downstream effects of
each SNP in a locus will be necessary.
Genetics alone will not provide all of the
answers, but if combined with careful study of
the downstream biology, it seems likely that new
pathways involved in disease biology will be
discovered – improving our understanding of
disease pathogenesis and potentially providing
new opportunities for therapeutic intervention.
UNRAVELLING DISEASE
PATHOGENESIS – THE GENETIC
CONTRIBUTION
Although the pathophysiology of CD is not fully
understood, the current hypothesis assumes a
complex interplay between environmental,
genetic and intestinal microbial factors, all of
which interact with the host’s immune system to
result in a pathological auto-inflammatory
response directed towards the intestine.18 During
the past decade, GWASs have identified multiple
SNPs that – by virtue of their proximity to genes
known to be involved in specific pathways –
have led to the implication of these pathways in
disease development. Some of these proposed
pathophysiological mechanisms will now be
discussed in more detail – especially those that
have made important contributions to our
current understanding of CD pathogenesis
(Table 1).
2018 | Vol. 7 | e1001
Page 2
ª 2018 The Authors. Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of
Australasian Society for Immunology Inc.
GWAS in Crohn’s disease B Verstockt et al.
Autophagy
Prior to genetic studies that identified ATG16L1 and
IRGM as susceptibility loci for CD,7,19 a role for
autophagy in disease pathogenesis had not been
envisaged. Autophagy is a well-described and
evolutionarily conserved process whereby
cytoplasmic components are engulfed by double-
membraned vesicles (autophagosomes) that then
fuse with lysozymes in order for their contents
(protein aggregates and damaged organelles) to be
degraded and recycled.20 Given the importance of
intestinal microbes in CD pathogenesis, it is notable
that autophagy also plays a role in clearance of
intracellular micro-organisms (a process known as
‘xenophagy’).21,22 Moreover, autophagy has also
been linked to endoplasmic reticulum (ER) stress23 –
another process that has been implicated in
intestinal inflammation and IBD.24 ER stress has
been shown to induce autophagy, and autophagy
reciprocally plays a role in resolving ER stress.25
Interestingly, Crohn’s disease risk SNPs seem to be
able to disrupt this balance, which can lead to
intestinal inflammation.26
When autophagy genes were first associated
with CD, the mechanism by which autophagy
altered disease risk was unknown. Several groups
therefore sought to investigate this by genetically
targeting ATG16L127–29 – the first autophagy gene
to be identified.7 Most of these studies used loss-
of-function approaches (i.e. ATG16L1 knockout or
knock-down) and while they provided interesting
insights into the role of autophagy in intestinal
inflammation, it was unclear as to how the results
might relate to the risk variant identified by
GWAS. This was because unlike most GWAS hits,
which are typically noncoding and thus presumed
to affect gene expression, the risk SNP in ATG16L1
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Figure 1. Basic principles of GWAS. GWAS has been made possible because of the haplotype structure of the human genome. Every
chromosome consists of multiple haplotypes – regions that are inherited together during meiosis. Within each haplotype, there are typically many
SNPs, which are co-inherited within the larger genetic region, and thus, their alleles are inherited nonrandomly (i.e. they are in linkage
disequilibrium). This means that it is possible to infer the genotypes at multiple SNPs within the haplotype (shown in grey) if the genotype at one
or more SNPs is known. GWAS SNPs (shown in black) are selected so as to tag each haplotype, but where association is observed, they are
unlikely to be the causal variant at the locus (shown in red). By genotyping SNPs from each haplotype in the genome in disease cases and healthy
controls, it is possible to identify SNPs where the allele frequency is significantly different between the cases and controls, and which are
associated with the disease.
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is a missense mutation that leads to a threonine
to alanine substitution at position 300 (rs2241880,
Thr300Ala or T300A).7 Missense mutations are
generally assumed to affect protein structure or
function due to the effect that an amino acid
substitution could have on protein folding – but
would not be expected to directly affect the
amount of the protein, as are typically modelled
with loss-of-function approaches. However, in this
case, it was subsequently shown that the missense
mutation does primarily affect the amount of
ATG16L1 protein within cells, rather than the
function of the protein per se, as the alanine
substitution makes ATG16L1 protein more
susceptible to caspase-3-mediated degradation.30
This in turn reduces ATG16L1 levels, and hence
autophagy, during periods of cellular stress (e.g.
inflammation) and results in defective clearance
of intracellular pathogens and increased
inflammatory cytokine production.30 A similar
effect on intracellular pathogen clearance was
also reported at the IRGM locus. Here, the
original GWAS association (rs1000113 C>T) was
shown to be in perfect linkage disequilibrium
with a synonymous exonic SNP (rs10065172 C>T)
that is located within a binding site (‘seed
sequence’) for a microRNA, miR-196. This
microRNA was found to be highly expressed
within the intestinal epithelia of patients with CD,
and its expression was shown to anti-correlate
with IRGM mRNA levels – consistent with a
physiological role in repressing IRGM.31
Interestingly, the disease-associated variant (T) at
rs10065172 disrupted the miR-196 seed sequence,
so that miR-196 could not bind and resulted in
carriers of the CD-associated variant being unable
to repress IRGM mRNA levels, which led to
impaired autophagy and a failure to clear
intracellular bacteria.31 These examples, where the
functional consequences of a risk allele have been
elucidated, are relatively uncommon, but
highlight how the study of genetic variants can
uncover specific pathway defects that contribute
to CD pathogenesis.
In addition to helping resolve the role of
autophagy in CD pathogenesis, the identification
of genetic risk variants in known autophagy
genes also led to the realisation that other
susceptibility genes, which had not previously
been linked to autophagy, might actually be
involved in this process. For example, NOD2 – the
first CD susceptibility gene to be discovered2–4 –
Table 1. Summary of IBD GWAS hits involved in autophagy, the IL-17/IL-23 axis/type 3 innate lymphoid cells and the failure to suppress of
aberrant immune responses
Chromosome SNP P value OR AF Candidate gene in/near locus
Autophagy 2 rs6752107 1.42E73 1.25 0.55 ATG16L1
5 rs11741861 2.94E37 1.25 0.05 IRGM
12 rs11564258 6.38E29 1.33 0.025 LRRK2
16 rs2066844 2.27E217 2.00 0.06 NOD2
IL-23/IL-17 Axis Type 3
innate lymphoid cells
1 rs11581607 8.76E175 0.46 0.05 IL23R, IL12RB2
1 rs4845604 1.21E17 0.88 0.13 RORC
5 rs56167332 7.17E50 1.17 0.35 IL12B
6 rs1819333 6.76E21 1.08 0.48 CCR6
9 rs75900472 4.70E48 1.16 0.13 JAK2
12 rs11614178 2.22E32 1.19 0.4 IL22, IFNG
17 rs12942547 5.51E22 1.1 0.55 STAT3, STAT5A, STAT5B
19 rs11879191 5.27E20 0.89 0.2 TYK2
21 rs7282490 2.35E26 1.1 0.39 ICOSLG
Failure to suppress aberrant
immune responses
1 rs3024505 2.99E50 1.22 0.19 IL10
4 rs7657746 3.00E13 1.1 0.20 IL2
7 rs1077773 5.96E9 0.93 0.48 AHR
10 rs12722515 3.76E10 1.1 0.85 IL2RA
15 rs17293632 2.71E20 1.11 0.14 SMAD3
16 rs529866 1.73E16 1.12 0.81 SOCS1
17 rs12942547 5.51E22 1.1 0.55 STAT3, STAT5A, STAT5B
18 rs7240004 1.01E10 0.94 0.34 SMAD7
21 rs2284553 2.14E16 1.12 0.60 IL10RB
Data are collated from Jostins et al.,11 Liu et al.,12 and Huang et al.17
Allele frequency (AF) refers to allele frequency in 1000 genomes CEU population of the allele for which odds ratio (OR) is reported.
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was principally thought to be an intracellular
pattern recognition receptor involved in defence
against bacteria,32 but it was subsequently shown
that NOD2 also interacts with ATG16L1 during
autophagosome formation.33–35
The identification of autophagy genes, and
specifically ATG16L1, also helped uncover the
important role that Paneth cells are thought to play
in Crohn’s disease. Paneth cells are located at the
base of intestinal crypts and are known to be
involved in mucosal defence, producing large
amounts of anti-microbial peptides, including
defensins.36 Early studies into the role of autophagy
in intestinal inflammation revealed that mice with
reduced Atg16l1 expression had morphologically
abnormal Paneth cells with reductions in the
number and size of secretory granules.37 Similar
defects were also noted in CD patients who were
homozygous for the ATG16L1 T300A variant.38
Interestingly, Paneth cell dysfunction has also been
reported in mice following deletion of a
transcription factor (Xbp1), which is involved in the
unfolded protein response (UPR) and thereby helps
to resolve ER stress.24 Indeed, it was subsequently
shown that CD-like ileitis spontaneously develops in
mice if the UPR and autophagy were simultaneously
compromised in Paneth cells, suggesting that the
balance between ER stress and autophagy is likely to
set an important threshold for initiating intestinal
inflammation.39
The realisation that autophagy plays an
important role in CD has also led to questions about
whether pharmacological manipulation of
autophagy could be used therapeutically. Studies
involving mouse models have shown that rapamycin
(sirolimus), which upregulates autophagy by
inhibiting mTOR, can ameliorate experimental
colitis.40,41 A beneficial effect of sirolimus has also
been reported in a case study of an adult with
refractory CD42 and a retrospective case series of
children with refractory IBD,43 although no
randomised placebo-controlled trials have yet been
performed. This, however, remains an active area of
research, not least because sirolimus is also known
to also have anti-fibrotic effects that could be
beneficial in CD – a trial investigating this is
currently underway (NCT02675153).
The IL-23/IL-17 axis, bridging the innate and
adaptive immune system
Early studies into the pathogenesis of IBD
identified differences in the ratio of T helper (TH)
1/TH2 cells in the intestinal mucosa of patients
with CD or UC, and corresponding differences in
their cytokine profiles.44–46 CD appeared to be a
TH1-associated disease with increased levels of
interferon-c and IL-12, while UC appeared to
more TH2-like – being characterised by increased
IL-5 and IL-13 production (although not IL-4).
Several animal models supported this hypothesis,
with an anti-IL-4 antibody showing therapeutic
benefit in oxazolone-induced colitis,47 which
histologically resembles UC, while the transmural,
CD-like colitis induced by 2,4,6 trinitrobenzene
sulphonic acid could be abrogated by an anti-IL-
12 antibody48 – a molecule that was subsequently
found to be effective in human CD trials.49
However, this hypothesis ultimately proved to be
overly simplistic, and it was soon realised that the
anti-IL-12 antibody would have also blocked IL-23
due to its target antigen being a common subunit
(p40) that is shared between these cytokines.50
Indeed, it was later shown that the effect upon IL-
23, a cytokine important in the development and
maintenance of mucosal effector TH17 cells, was
responsible for the therapeutic benefit in animal
models.51 Activated TH17 cells could also be
identified in the blood and intestine of CD
patients.52 Around this time, genetics provided
further support for a possible role of TH17 cells in
CD and UC, with numerous susceptibility variants
being identified within or near to genes
implicated in TH17 biology (e.g. RORC, IL23R,
IL12B, TYK2, JAK2, STAT3, CCR6 and ICOSLG,
Table 1).9,10 However, while these genetic
associations are consistent with a role for TH17
cells in CD pathogenesis, it is important to note
that the functional consequences of the risk
alleles at most of these loci have not yet been
elucidated. As such, we still need to confirm that
these genes are directly affected by the disease-
associated SNPs at these loci, and also that the
functional consequences of the risk alleles
specifically affect IL-23/IL-17 signalling, as several
of these genes are also involved in other
pathways (e.g. STAT3 is critical for IL-10
signalling). Accordingly, the precise role of TH17
cells in CD pathogenesis still needs to be fully
characterised, and in this context, it is notable
that antibodies which target a key TH17 cytokine,
IL-17, are ineffective in CD53 and yet are highly
effective in other TH17-driven diseases.
54
Another reason why the exact role of TH17 cells
remains obscure, despite several lines of evidence
appearing to implicate them in CD pathogenesis,
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is because of the discovery of innate lymphoid
cells (ILCs). These cells belong to the lymphoid
lineage but do not express antigen-specific
receptors and are therefore not part of the
adaptive immune system.55 Nonetheless, subsets
of ILCs exist that mirror T-cell subsets in terms of
their cytokine secretion profiles.55 Type 3 ILC cells
(ILC3s), for example, correspond to TH17 cells in
that they can express RORct, produce IL-17 and
IL-22, and are responsive to IL-23.55 Moreover,
these cells have been shown to be responsible for
bacteria-driven colitis in mice that lack T cells56
and to selectively accumulate in the intestine of
patients with active CD.57 Nevertheless, their
specific contribution to CD pathogenesis – as
distinct from that of TH17 cells – is difficult to
ascertain because not only are they greatly
outnumbered by T cells in the intestine, but many
of the methods used to deplete them will also
affect T cells (and vice versa) making it difficult to
disentangle their relative contributions. To
complicate things further, it appears that other
ILC subsets may also play a role in CD
pathogenesis. For example, type 1 ILCs (ILC1s),
which resemble TH1 cells in that they express the
transcription factor T-bet, respond to IL-12 and
can produce interferon-c, are substantially
increased in the intestine of patients with CD.58
For this reason, although the exact role of ILCs in
IBD pathogenesis has not been fully established,
this remains an active area of research – especially
as they might provide tissue-specific therapeutic
targets for some patients.
The failure to suppress aberrant immune
responses
It has been estimated that the human body
contains ~40 trillion bacteria, of which the vast
majority are located within the intestine.59 This
means that there are actually more bacteria in our
bodies than human cells and illustrates why the
intestine presents such a challenge to the immune
system. In order to be able to mount an
appropriate immune response to intestinal
pathogens, for example, there have to also be
mechanisms to prevent aberrant responses to
nonpathogenic gut commensals in order to
preserve health. Disrupting such control
mechanisms is known to lead to colitis in animal
models – for example, if the Il10 gene is deleted60
or if regulatory T cells are absent.61 Results from
GWAS studies have demonstrated that disruption
of these anti-inflammatory mechanisms is also
likely to be involved in the development of CD.
For example, several genes involved in IL-10
signalling (the anti-inflammatory cytokine which
when deleted leads to colitis in animal models) lie
near to GWAS hits, including IL10, IL10RB, STAT3
and TYK2.11,62 Although the functional
consequences of these SNPs have not been
determined, the notion that IL-10 signalling may
be defective in IBD is supported by other genetic
studies. For example, private missense mutations
in genes encoding components of the IL-10
receptor (IL10RA or IL10RB) have also been shown
to cause a severe, early-onset form of IBD in
consanguineous families due to abrogation of
IL-10 signalling.63 Other anti-inflammatory
cytokines – and genes involved in their signalling
pathways – have also been identified within CD-
associated genetic loci, including IL22 (another
member of the IL-10 cytokine family) and SMAD3
and SMAD7, which are important components of
TGFb signalling. Indeed, SMAD7, which inhibits
TGFb signalling and is expressed at high levels in
the intestines of patients with IBD,64 has been
shown to be an effective therapeutic target via an
antisense oligonucleotide (Mongersen) that binds
to and degrades SMAD7 mRNA.65
Although several cell types are known to play a
role in suppressing exuberant immune responses,
including M-2 macrophages, certain ILC
populations and regulatory B cells, by far the
most studied immunosuppressive cell type are
regulatory T cells (Tregs). Several GWAS hits also
highlight the importance of Tregs in IBD
pathogenesis. For example, it is known that IL-2
signalling is critical for maintaining Treg
numbers66 and for mediating their suppressor
function via activation of STAT5,67 and GWASs
have identified IBD-associated loci that contain
IL2, IL2RA (part of the IL-2 receptor) and STAT5.11
Moreover, IL-10 signalling – discussed earlier – is
also important in conferring Tregs with the ability
to suppress TH17-mediated inflammation
68 and in
mediating that suppression.69 Additionally, there
is a growing realisation that plasticity exists
within T-cell subsets and particularly between
Tregs and TH17 cells, with evidence that TH17 cells
can transdifferentiate into Tregs as inflammation
resolves – a process that involves signalling
through the aryl-hydrocarbon receptor (AHR),
which also harbours a genetic association with
IBD.12 Further evidence of the role of Tregs in
intestinal inflammation can also be found in
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patients who carry rare missense mutations in
FOXP3, which encodes the master transcription
factor for naturally occurring Tregs. The resulting
syndrome, termed ‘immunodysregulation,
polyendocrinopathy, enteropathy, X-linked
syndrome’ or ‘IPEX’,70 is characterised by an
autoimmune enteropathy as well as several other
severe autoimmune phenomena.
Based on these and other insights, Tregs are
now also being studied as potential therapies in
IBD. Different strategies have been proposed
including inducing Tregs ex vivo from na€ıve T cells
using an unrelated antigen71 or isolating
thymically derived Tregs and expanding them
before re-infusing them back into patients.72
These expanded Tregs have been shown to be
able to suppress the activation and proliferation
of intestinal T cells from CD patients in vitro and
to have an epigenetically stable FOXP3 locus,
theoretically limiting the possibility for TH17
conversion.72 However, full clinical trials using
these approaches have yet to be performed, and
it should be noted that in other disease areas,
infused regulatory T cells have not shown the
same efficacy as had been observed in vitro or in
animal models.73
OVERLAP WITH OTHER IMMUNE-
MEDIATED DISEASES – SHARED
FEATURES OF AUTOIMMUNITY?
In addition to highlighting pathways that are
likely to be important in the development of CD,
GWAS has also provided insights into how the
genetic architecture of CD relates to that of other
autoimmune diseases.16 For example, while most
IBD susceptibility loci are shared between CD and
UC, it is notable that SNPs that are implicated in
autophagy seem to be specific to CD, while SNPs
that are located in, or near to, genes involved in
epithelial barrier function tend to be more UC
specific.74 Interesting overlaps have also been
noted in other nonintestinal diseases. This is
perhaps best exemplified by the IL-23/IL-17 axis, to
which multiple autoimmune diseases have been
linked, including psoriasis (SNPs in or near to
IL23R, IL12B, TYK2 and STAT3), ankylosing
spondylitis (SNPs in or near to IL23R, IL12B, TYK2
and JAK2) and multiple sclerosis (SNPs in or near
to IL12B, IL12A, TYK2 and STAT3). Overlap with
some of these diseases, such as psoriasis or
ankylosing spondylitis, was unsurprising since
these diseases share certain clinical and
pathogenic features with CD, although overlap
with other diseases, such as multiple sclerosis, was
less expected. However, it is important to note
that interpreting this overlap is not
straightforward. Indeed, just because the same
gene is implicated in several diseases does not
mean that common genetic haplotypes (and
biological mechanisms) are responsible for these
associations. For example, although both CD and
psoriasis are both associated with multiple SNPs in
TYK2, these signals are largely distinct.11,75
Indeed, the only shared susceptibility SNP at this
locus (rs12720356, a missense variant) shows
discordant effects, with the risk allele for CD
being protective for psoriasis. Discordant effects
at the same SNP are surprisingly common in
autoimmune disease genetics and present an
additional challenge to understanding how
genetic variation can influence disease
susceptibility. For example, a SNP in STAT3,
rs744166, is associated with both CD and multiple
sclerosis, but the risk allele for CD is protective for
multiple sclerosis and vice versa.13,76 As such,
while it is undoubtedly interesting that
overlapping associations are detectable across
distinct diseases – either at the SNP or gene level
– much more work needs to be done to
determine the true extent of any biological
overlap. This work will be particularly important
given emerging evidence that drugs targeting
these ‘shared’ pathways may have very different
effects between diseases, such as the anti-IL17
antibody secukinumab, which is highly effective in
psoriasis but entirely ineffective in CD.53,54
MORE WORK TO DO
Despite the successes described above, much more
work needs to be done to fulfil the original goal
of GWAS in Crohn’s disease – to learn how
genetic variation contributes to disease biology.
For example, because our ability to identify
disease-associated variants has far outstripped our
ability to characterise their functional effects, we
still do not know the biological consequences for
most of the associated variants. This bottleneck
has led to the temptation to assume that we
know which gene is mediating the effect at a
particular locus – often because one particular
gene might be involved in a familiar aspect of
disease biology – but the reality is that there is
often little or no evidence to support this. Indeed,
in many cases, we are not even certain of which
ª 2018 The Authors. Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of
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SNP – or combination of SNPs – is responsible for
driving the genetic association since the SNPs
included on GWAS chips are simply tags for
haplotypes that may contain hundreds of
associated variants (Figure 1). Fine-mapping
studies have sought to resolve the genetic
associations within GWAS regions, with some
success,11,17 although strong linkage
disequilibrium has prevented the identification of
a single causal variant for most loci.17 Similarly,
there have been several efforts to understand
how genetic variation at a locus might affect the
expression of nearby genes – especially since most
GWAS hits (and their associated haplotypes) do
not appear to affect the coding sequence of
genes. This has commonly been done by
combining genotypic data with transcriptomic
data in order to identify correlations between SNP
genotypes and gene expression. However, even
when genetic variants are identified that correlate
with gene expression (termed expression
quantitative trait loci or eQTLs), strong linkage
disequilibrium usually means that it is not possible
to identify which of the SNPs within the
haplotype is responsible for the observed
effect.77,78 As such, while these studies can be
useful for identifying the genes that are affected
by genotype at a particular SNP, they usually
cannot identify the causal SNP within the
haplotype. Moreover, these studies have revealed
that many eQTL effects are only detectable in a
specific cell type and/or in the presence of a
specific stimulus,77,78 meaning that a causal
variant could easily be overlooked if the wrong
tissue or condition is being examined.79
For these reasons, a major goal of future studies
should be to functionally dissect the consequences
of disease-associated genetic variation at each
locus in order to avoid incorrectly attributing an
association with a gene that is not involved and/
or overlooking an important gene that is involved
in an unknown aspect of disease biology because
it might appear irrelevant. This is no small task, as
it will need to include identification of both the
cell types in which the effect is relevant and also
the context (e.g. during a particular stage in
development or in the presence of a particular
stimulus). Examples of such studies have been
performed in other fields,80–82 but will need to be
embraced by IBD researchers in order to
understand the underlying mechanisms and
functional consequences of disease-associated
noncoding genetic variation (Figure 2).
Another ongoing challenge in CD genetics is to
understand why the genetic variants identified to
date account for only a small proportion of the
variance of CD (the portion of heritability
attributable to genetic variation). It has been
estimated that even with such a high number of
disease-associated SNPs, we have only accounted
for 26% of CD variance.83 The remainder, which
has been termed ‘missing heritability’, still has to
be accounted for, and there are several
hypotheses that might explain this. First, because
GWAS studies perform a univariate analysis, they
cannot account for gene–gene interactions
(epistasis) that might substantially alter the effect
size of a given mutation. For example, in
psoriasis, an epistatic interaction has been
identified between genetic variants in ERAP1 and
MHC-C, which has a much larger effect size that
either of the variants in isolation.84 Second,
gene–environment interactions would similarly be
expected to alter the effect size attributed to a
particular variant if the environmental condition
specifically interacted with the pathway affected
by a causal SNP. For example, tobacco smoke – a
known environmental risk factor for CD – has
been shown to modify the association between
64 SNPs and CD, including NOD2 and the HLA
region.85 Third, despite the name, most GWAS
chips do not actually provide genome-wide
coverage. As such, it is likely that some of the
missing heritability simply lies in regions that
have not been analysed to date, either because
they are difficult to impute or because they are
poorly covered on GWAS chips.15 For instance,
GWAS studies in CD have not yet analysed any
SNPs on the sex chromosomes, even though these
are likely to contain some disease-associated
variants.86 Indeed, one of the few studies to
include the chromosome-X was a meta-analysis of
10 paediatric diseases, including CD and UC,
which identified a SNP in CD40LG, an X
chromosome gene, that was associated with CD,
UC and coeliac disease.87 Similarly, some regions,
such as the Fc receptor gene cluster or the KIR
genes, contain highly repetitive sequences are
difficult to genotype using standard approaches.
Fourth, it has been proposed that rare variants –
which are not included on GWAS chips but
which could have much larger effect sizes –
might account for some of the missing
heritability. However, several studies have now
been performed to attempt to identify rare
disease-associated variants, but without much
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success88,89 – mirroring the situation in other
diseases.90 Fifth, because most GWAS SNPs are
proxies for the true causal variant, estimates of
variance based on these are likely to
underestimate the true attributable risk at each
locus. With the introduction of fine-mapping
studies, though, this problem should soon be
resolved.
All of these possibilities seek to address the
issue of missing heritability from the perspective
of identifying missing disease risk. However, it is
equally possible that some of the missing
heritability might be a consequence of our
heritability calculations being incorrect. For
instance, estimates of SNP heritability – the
proportion of disease variance accounted for by
risk SNPs – assume that gene–gene interactions
do not occur, even though it is widely accepted
that they probably do. If heritability calculations
are performed using a model that allows
epistasis, then it has been shown that up to
80% of the missing heritability in CD can be
accounted for.91 Similarly, if the effects of minor
allele frequency (MAF), LD and genotype
certainty are factored into calculations of SNP
heritability, this also tends to lead to higher
estimates.92
GWAS IN DIFFERENT POPULATIONS
During most of the twentieth century, the
incidence of CD rose steadily in the Western
world but was relatively low in developing
countries.93 However, recently the incidence of CD
in newly industrialised regions has been rising
rapidly – particularly in South East Asia, South
America and the Middle East – such that
previously noted ethnic differences appear to be
narrowing.93 This increase in the incidence of CD
is also detectable when comparing first- and
second-generation immigrants from low risk areas
who emigrate to countries with higher incidence
of IBD94 and highlights the importance of
environmental factors in CD development.
Notably, the vast majority of GWAS studies in IBD
have been performed in Caucasian populations
(indeed GWAS chips were mostly designed based
on Caucasian haplotype structure). Of the few
studies that have been performed in individuals
of non-Caucasian descent, the results suggest that
there may be some important population-based
differences in the genetic risk of CD. For example,
a meta-analysis of Asian genetic studies revealed
that variants in ATG16L1 and NOD2, which are
associated with CD in Caucasian populations, were
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Figure 2. Moving from SNPs to biology. Due to linkage disequilibrium, it is not possible to know which is the causal SNP at an associated locus
without additional studies such as fine-mapping or functional analyses to systematically dissect the effects of each variant. Once this is known the
mechanism by which the effect occurs and the downstream cellular consequences can be determined – for example, a SNP might introduce a
binding site for a tissue-specific transcription factor (TF) and the resulting effect on gene expression could confer an altered cellular phenotype
that could provide new insights into disease biology or provide an opportunity for therapy.
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not associated in Han Chinese, Japanese, South
Korean, Indian and Malaysian CD populations.95
Similarly, a GWAS in Ashkenazi Jewish CD patients
identified five novel genetic regions not
previously found in non-Jewish Caucasian CD
populations.96 A recent trans-ethnic GWAS
incorporating 86 640 individuals of European
descent and 9846 individuals of East-Asian, Indian
or Iranian descent also highlighted a shared
genetic risk across European and non-European
cohorts for most IBD risk loci, although genetic
heterogeneity was observed – both in terms of
allele frequency and/or effect size – between at
several loci, including NOD2, TNFSF15, ATG16L1,
IL23R and IRGM.12 In contrast, a GWAS in 2345
African Americans with IBD confirmed known risk
loci but did not reveal any new variants
associated with CD susceptibility.97 Clearly, larger
studies will be necessary to better explore the
commonalities and differences in the genetic
variance of CD between populations, and these
should ideally be performed using GWAS chips
that are predicated upon the haplotype structure
of the population being studied or whole genome
sequencing, so as not to overlook the
contribution of variants that are specific to non-
Caucasian populations.
PHARMACOGENETICS
Aside from disease susceptibility, GWASs have also
been used to try to identify genetic variants that are
associated with specific side effects to medications
commonly used to treat CD. Interest in this area was
initially driven by studies in other fields that
identified low-frequency variants with large effect
sizes that were responsible for well-recognised side
effects98 and by previous work that had
demonstrated the clinical value of genotyping for
mutations in TPMT that alter the risk of thiopurine-
induced myelosuppression.99 GWAS studies have
since identified genetic variants in NUDT15 that
alter the risk of thiopurine-induced
myelosuppression,100 and in the MHC that alter the
risk of thiopurine-induced pancreatitis (HLA-
DQA1*02:01-HLA-DRB1*07:01)101 and 5-ASA-
induced nephrotoxicity (HLA-DRB1*03:01).102
Interestingly, the HLA-DRB1*03 allele has also been
associated with the development of antibodies
against infliximab – an anti-TNF-a monoclonal
antibody that is one of the most effective
treatments for CD. Patients carrying the risk
haplotype were almost seven times more likely to
develop antibodies, which could potentially
neutralise the drug and lead to a loss of efficacy.103
In addition to studying the genetic contribution
to drug side effects, efforts have also been made
to identify a genetic contribution to treatment
response. So far, however, most of these studies
have used a candidate gene approach,
investigating individual genes or groups of genes
– often those linked to CD susceptibility – rather
than adopting a genome-wide approach.104
Similar to disease susceptibility, it seems unlikely
that a single variant will determine the efficacy of
CD therapies, and therefore, a genome-wide
approach will be important. Moreover, there is no
reason to suspect that variants influencing
response to treatment would be the same as those
that alter disease susceptibility, and thus, it was
unsurprising when a polygenic risk score based on
140 CD risk loci did not associate with response to
anti-TNF therapy.105 To date, a genome-wide study
of response to anti-TNF therapy has not been
performed in IBD, although a study based on the
Illumina immunochip (a custom designed
genotyping chip containing variants that have
been associated with autoimmune diseases) did
provide some encouraging results,106 though
further validation and larger independent
discovery cohorts will be important. In rheumatoid
arthritis (RA), such a study has already been
performed and identified eight loci that were
associated with response to infliximab.107 A similar
study has also been reported in abstract form for
ustekinumab, an anti-IL12/23 antibody, in which
two loci were shown to be associated with
response to therapy in CD patients.108
In summary, although attempts to understand
the genetic contribution to side effects or
treatment response are far less advanced than
equivalent studies in disease susceptibility, early
studies have provided plenty of reason for
optimism. Indeed, if genome-wide approaches
were to be adopted in suitably powered cohorts,
it seems probable that genetic variants will be
discovered that could both shed light on the
biology responsible for responses to treatment
and also potentially provide useful biomarkers for
screening.
SUBPHENOTYPES: MOVING BEYOND
DISEASE SUSCEPTIBILITY
Despite the success of GWAS studies into the
genetic contribution to disease susceptibility,
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there are several other aspects of CD biology that
have been proposed to have a genetic component
but which – until recently – had not been studied
by GWAS. For example, the distribution of Crohn’s
disease within the intestine and the clinical course
of disease following diagnosis (prognosis) have
both been shown to follow similar patterns within
families109 but have been largely overlooked in
favour of successively larger meta-analyses into
disease susceptibility. Part of the reason for this
has been the assumption that susceptibility
variants would also influence other aspects of
disease.110 For example, it was assumed that the
total burden of susceptibility variants would
determine disease course, so that individuals who
carry more risk SNPs would experience a worse
prognosis. This hypothesis has been shown to be
correct for qualitative traits such as height,111 but
in CD – and other diseases – it would only be
correct if susceptibility and prognosis were on a
continuous spectrum and thus influenced by the
same variants. If, however, this assumption is
incorrect, then it would be very unlikely for SNPs,
which influence disease prognosis to be identified
through comparison of unstratified cases with
controls.112 Instead, it would be necessary to
directly compare subsets of patients based on
phenotypic differences – a so-called within-cases
analysis (Figure 3).
To date, there have only been a few examples
of using within-cases analyses in CD genetics. The
largest study was performed by the International
IBD Genetics Consortium and investigated the
contribution of a large number of autoimmune
disease-associated SNPs to CD distribution, age of
onset and behaviour (i.e. inflammatory,
stricturing or fistulating). Although this
identified little or no genetic association with
disease behaviour, it did identify three loci that
were associated with disease location (NOD2,
MHC and MST1) and showed that a genetic risk
score representing the sum of all known risk
alleles for IBD showed a strong association with
disease location.113
Despite the importance of CD prognosis in
determining patient well-being, most of the
studies into the genetic contribution to prognosis
have focused on small numbers of susceptibility
SNPs in relatively small numbers of patients and
have unsurprisingly provided inconsistent
results.114–116 One of the few replicable
associations identified was between variants in
NOD2 and need for surgery,117 although this was
subsequently shown to be entirely driven by the
association between NOD2 and ileal disease
(which is most commonly treated with surgery).
Indeed, if this analysis is stratified by disease
location, then no association between disease
course and NOD2 variants is detectable.113 For
this reason, we elected to investigate the
genetics of CD prognosis using a within-cases
analysis in which the genetic profiles of patients
with contrasting courses of CD would be
compared. This was first done as a candidate
gene study and identified a noncoding SNP in
FOXO3 that was not a disease susceptibility
variant, but which was associated with a milder
course of CD118 – an association that has since
been replicated.119,120 Functional studies into the
biological consequences of this SNP, which does
not affect disease susceptibility, identified a
FOXO3-driven pathway that abrogated
inflammatory responses in monocytes via TGFb1
and led to reduced TNF-a and IL-6 production in
carriers of the mild CD-associated allele.118
Interestingly, this SNP was also shown to
associate with good prognosis in RA (another
TNF-a-driven disease121) and with poor prognosis
in malaria (in which TNF-a is anti-parasitic).118
Since then, this variant has also been
independently associated with clinical outcome in
tuberculosis,122 another disease in which TNF-a is
known to be important. Based on this result, we
then extended the analysis to a genome-wide
level and identified a further three loci that were
significantly associated with prognosis in CD
(XACT, a region upstream of IGFBP1 and the
MHC region).120 Strikingly, none of these variants
were associated with disease susceptibility, and
conversely, none of the CD susceptibility variants
were associated with prognosis in our analysis,
either individually or collectively. This
demonstrated that the genetic contribution to
prognosis comes from loci that are distinct from
those that drive disease development, which in
turn has important implications for our
understanding of disease pathogenesis and could
provide new opportunities for drug development
and/or personalised medicine. In the future,
larger within-cases analyses will be important to
further resolve the genetic contribution to
clinically important disease subphenotypes, but
the success of these will critically depend on
there being detailed, high-quality and consistent
phenotypic data, else they are likely to provide
(falsely) negative results.
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CONCLUSIONS
During the past decade, our understanding of CD
pathogenesis has benefitted greatly from the
advent of GWAS – success that has been possible
thanks to large-scale international collaboration.
This has resulted in several novel insights into
disease biology, which are now being investigated
as therapeutic targets. However, it is important
not to think that the job is done. There is much
work left to do in order to fulfil the original goals
of GWAS and learn more about disease biology,
from determining the functional consequences at
each associated locus to exploring genetic risk in
other populations to identifying the genetic
contribution to other important aspects of disease
biology, such as prognosis. Much has been
accomplished since the first CD GWAS 10 years
ago, but much more should be accomplishable in
the next 10 years if we make the most of the
discoveries to date.
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